• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Artiva Biotherapeutics Inc.

    5/15/25 4:44:26 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARTV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Artiva Biotherapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    04317A107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    04317A107


    1Names of Reporting Persons

    venBio Global Strategic Fund III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,198,975.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,198,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,198,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    04317A107


    1Names of Reporting Persons

    VENBIO GLOBAL STRATEGIC GP III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,198,975.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,198,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,198,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    04317A107


    1Names of Reporting Persons

    VENBIO GLOBAL STRATEGIC GP III, LTD
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,198,975.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,198,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,198,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    CO, HC


    SCHEDULE 13G

    CUSIP No.
    04317A107


    1Names of Reporting Persons

    Adelman Robert J
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,198,975.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,198,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,198,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    IN, HC


    SCHEDULE 13G

    CUSIP No.
    04317A107


    1Names of Reporting Persons

    GOODMAN COREY S
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,198,975.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,198,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,198,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    IN, HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Artiva Biotherapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    5505 Morehouse Drive, Suite 100, San Diego, California, 92121
    Item 2. 
    (a)Name of person filing:

    This Statement is filed on behalf of the following persons (collectively, the "Reporting Persons"): i. venBio Global Strategic Fund III, L.P. ("Fund III"); ii. venBio Global Strategic GP III, L.P. ("General Partner III"); iii. venBio Global Strategic GP III, Ltd. ("GP Ltd. III"); iv. Robert Adelman ("Mr. Adelman"); and v. Corey Goodman ("Mr. Goodman"). This Statement relates to shares of Common Stock ("Shares") directly beneficially owned by Fund III. General Partner III is the sole general partner of Fund III, and GP Ltd. III is the sole general partner of General Partner III. Mr. Adelman and Mr. Goodman are directors of GP Ltd. III (collectively, the "Directors"). Accordingly, each of General Partner III, GP Ltd. III, and the Directors may be deemed to indirectly beneficially own the Shares reported herein. Dr. Aaron Royston is also a director of GP Ltd. III but disclaims beneficial ownership over the securities held by Fund III.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each Reporting Person is c/o venBio Partners, LLC, 1700 Owens Street, Suite 595, San Francisco, CA 94158.
    (c)Citizenship:

    Each of Fund III and General Partner III is a Cayman Islands exempted limited partnership. GP Ltd. III is a Cayman Islands exempted company. Each of the Directors is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    04317A107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of March 31, 2025, each of the Reporting Persons may be deemed to beneficially own 1,198,975 Shares. Each Reporting Person disclaims beneficial ownership of such securities except for the Shares, if any, such Reporting Person holds of record.
    (b)Percent of class:

    The percentages set forth in Line 11 of the cover sheets are based on 24,363,119 Shares outstanding as of March 31, 2025, as reported in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Line 5 of cover sheets.

     (ii) Shared power to vote or to direct the vote:

    See Line 6 of cover sheets.

     (iii) Sole power to dispose or to direct the disposition of:

    See Line 7 of cover sheets.

     (iv) Shared power to dispose or to direct the disposition of:

    See Line 8 of cover sheets.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See disclosure in Item 2 hereof.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    venBio Global Strategic Fund III, L.P.
     
    Signature:/s/ David Pezeshki
    Name/Title:David Pezeshki, as attorney-in-fact for Corey Goodman and Robert Adelman, Directors of the General Partner of the General Partner
    Date:05/15/2025
     
    VENBIO GLOBAL STRATEGIC GP III, L.P.
     
    Signature:/s/ David Pezeshki
    Name/Title:David Pezeshki, as attorney-in-fact for Corey Goodman and Robert Adelman, Directors of the General Partner
    Date:05/15/2025
     
    VENBIO GLOBAL STRATEGIC GP III, LTD
     
    Signature:/s/ David Pezeshki
    Name/Title:David Pezeshki, as attorney-in-fact for Corey Goodman and Robert Adelman, Directors
    Date:05/15/2025
     
    Adelman Robert J
     
    Signature:/s/ David Pezeshki
    Name/Title:David Pezeshki, as attorney-in-fact
    Date:05/15/2025
     
    GOODMAN COREY S
     
    Signature:/s/ David Pezeshki
    Name/Title:David Pezeshki, as attorney-in-fact
    Date:05/15/2025

    Comments accompanying signature:  This Schedule 13G was executed by David Pezeshki on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.
    Exhibit Information

    Exhibit 1: Joint Filing Agreement Exhibit 2: Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

    Get the next $ARTV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARTV

    DatePrice TargetRatingAnalyst
    12/30/2024$20.00Buy
    H.C. Wainwright
    8/13/2024$21.00Buy
    Jefferies
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    8/13/2024Buy
    TD Cowen
    8/13/2024$18.00Outperform
    Wedbush
    8/13/2024$23.00Buy
    Needham
    More analyst ratings

    $ARTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

      SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. EDT. Members of the Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the "Investor

      5/28/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

      64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL Median duration of response for AlloNK + rituximab not yet reached and is at least 19.4 months, in line with approved auto-CAR-T therapies in aggressive B-NHL AlloNK's activity and well-tolerated safety profile in aggressive B-NHL patients support the potential to deliver deep B-cell depletion in a refractory autoimmune population in outpatient community settings SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose

      5/13/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

      IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

      5/8/25 8:00:00 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:27:11 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner 5am Partners Vi, Llc converted options into 1,058,284 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $9,999,996 worth of shares (833,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:15:09 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Venbio Global Strategic Fund Iii, L.P. bought $4,999,992 worth of shares (416,666 units at $12.00), converted options into 1,058,284 shares and acquired 461,687 shares (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/22/24 8:26:49 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

      12/30/24 7:13:58 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

      Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

      8/13/24 7:24:03 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Artiva Biotherapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Artiva Biotherapeutics with a rating of Overweight and set a new price target of $23.00

      8/13/24 7:23:42 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

      SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      11/14/24 4:56:18 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Artiva Biotherapeutics Inc.

      SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      9/3/24 4:18:05 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

      SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      8/1/24 7:00:07 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Banerjee Subhashis was granted 50,000 shares (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      4/25/25 5:07:02 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Banerjee Subhashis

      3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      4/25/25 5:03:53 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Aslan Fred was granted 200,000 shares, increasing direct ownership by 92% to 416,665 units (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      3/7/25 4:35:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Artiva Biotherapeutics Inc.

      SCHEDULE 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      5/15/25 4:44:26 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Artiva Biotherapeutics Inc.

      10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      5/8/25 8:06:33 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      5/8/25 8:03:54 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

      IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

      5/8/25 8:00:00 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

      SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

      4/8/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

      SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph

      1/29/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care